US 2018/0021421 A1 · ATTENUATED VACCINES TO PROTECT AGAINST TICK-BORNE EHRLICHIA SPECIES INFECTIONS

Abstract

Attenuated vaccines to protect vertebrate animals and people against tick-born rickettsial, Ehrlichia and Anaplasma species infections is disclosed. Also disclosed are methods to modify the organism to achieve the desired immunity through the modification of a novel genetic region involved in pathogenesis. These compounds represent a needed vaccine against an organism causing life-threatening febrile illness in humans and animals, and also represent the potential to develop new classes of drugs targeting the gene products of genes Ech_0660, Ech_0379, and Ech_0230, and their homologs of other related rickettsial pathogens.

Claims23

Dependent claims

An immunogenic composition useful to elicit an immune response against Ehrlichia infection in a subject, said composition comprising live, attenuated E. chaffeensis dispersed in a pharmaceutically-acceptable carrier, said live, attenuated E. chaffeensis comprising a mutation in one or more target genes that results in attenuated growth of the bacterium in a vertebrate host organism.

Dependencies are inferred from the claim text.

Facts

Application

15/544,090Filed 19 Jan 2016

Priority

19 Jan 2015

Published

25 Jan 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

A61K 39/0233
Bacterial antigens: rickettsiales, e.g. Anaplasma
A61K 2039/522
Bacterial cells; Fungal cells; Protozoal cells: avirulent or attenuated
A61K 2039/552
Characterised by the host/recipient, e.g. newborn with maternal antibodies: veterinary vaccine
A61K 2039/575
Characterised by the type of response, e.g. Th1, Th2: humoral response

Attenuated vaccines to protect against tick-borne ehrlichia species infections

Life of this patent

Attenuated vaccines to protect against tick-borne ehrlichia species infections

Life of this patent

Abstract

Claims23